Pfizer Australia works with some of Australia's best and brightest scientists, clinicians and investigators to discover and develop new medicines to prevent, treat and cure human diseases. Hear from our people about how we’re making a difference.
Pfizer is a significant contributor to the conduct of clinical trials in Australia. Clinical trials are human tests that help doctors understand if a new medicine is more effective or safer than existing medicines or treatments, and to determine the appropriate dosage of the new medicine.
Results from clinical trials can lead to the development of medicines that can prevent death and also improve the lives of people suffering from a diverse range of challenging medical conditions.
Pfizer Australia is a heavy investor in Australian-based medical research and development (R&D). Between 2005 and 2015, Pfizer’s Worldwide Research and Development has funded approximately $90 million in R&D projects in Australia (excluding matching funding and the cost of clinical trials).
In 2014, Pfizer Australia awarded three Australasian Pediatric Endocrine Care (APEC) Research Grants of $50K each to the best and brightest researchers in pediatric endocrinology.
Melbourne’s Monash University is the first academic institution outside the United States to join Pfizer’s network of research partners under the Pfizer Centers for Therapeutic Innovation (CTI).
The CTI brings together leading academic medical centres and disease foundations, along with Pfizer scientists, with the aim of translating promising science into clinical candidates.
Under the CTI initiative Pfizer has also formed a partnership with the University of Queensland (UQ) to advance drug discovery in Australia. The agreement with UniQuest, UQ’s commercialisation arm offers new opportunities to develop effective treatments for challenging medical conditions that affect people around the world.